Pharmaceutical industry

Ottawa blocks Trump plan to allow bulk U.S. import of cheaper prescription drugs from Canada

Trump makes late-term bid to lower prescription drug costs

Pharmaceutical industry offers Ottawa $1-billion to scrap pending drug pricing rules, documents show

Developing a coronavirus vaccine is just the first step – distribution presents a whole new challenge

McKesson says cost of opioid settlements could reach $21-billion

Britain starts accelerated review for AstraZeneca’s potential COVID-19 vaccine

U.S. to charge Teva with conspiring to raise prices of generic drugs, sources say

Johnson & Johnson buying Momenta Pharmaceuticals for around $6.5-billion

U.S. states reportedly seeking $26.4-billion from drug firms in opioid litigation

Chairman of China’s Sinopharm rules out high price for potential coronavirus vaccine

Taro Pharmaceuticals to pay more than $200-million to settle U.S. probe over fixing prices of generic drugs

Gilead begins testing inhalable form of remdisivir for treating COVID-19

EU secures potential COVID-19 drugs from Roche, Germany’s Merck: source

Bellus stock drops 72% after highly anticipated drug disappoints in human trials

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

Aurora Cannabis to close facilities, lay off 700 workers in restructuring

Repare Therapeutics seeks to raise up to US$152-million in Nasdaq share offering

Lilly says COVID-19 treatment could be authorized for use as soon as September

Gilead signs deals with generic drugmakers to scale up COVID-19 drug supply

Canopy Growth says two top executives have left the cannabis firm

Bausch Health reports $152-million first-quarter loss due to COVID-19

Gilead working to make trial COVID-19 treatment remdesivir ‘accessible and affordable’

Eli Lilly lifts 2020 profit forecast; coronavirus fuels stockpiling of its medicines

Rush to beat COVID-19 is unprecedented in pharmaceutical industry, veteran executive says

Generic drug makers win EU approval to co-operate in coronavirus fight

Trump’s touting of unproven drug for COVID-19 has its own side effects

Europe ‘panicking’ over India’s pharmaceutical export curbs, industry group says

Gilead buys cancer drug developer Forty Seven for $4.9-billion

Trump administration advances plan to import cheaper Canadian prescription drugs